Cargando…

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

Until recently, distant metastatic melanoma was considered refractory to systemic therapy. A better understanding of the interactions between tumors and the immune system and the mechanisms of regulation of T-cells led to the development of immune checkpoint inhibitors. This review summarizes the cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gellrich, Frank Friedrich, Schmitz, Marc, Beissert, Stefan, Meier, Friedegund
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019511/ https://www.ncbi.nlm.nih.gov/pubmed/31947592 http://dx.doi.org/10.3390/jcm9010223

Ejemplares similares

Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment
por: Steininger, Julian, et al.
Publicado: (2023)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021)

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
por: Tunger, Antje, et al.
Publicado: (2018)

Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
por: Kuske, Marvin, et al.
Publicado: (2018)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
por: Schulz, Alexander, et al.
Publicado: (2022)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
por: Moritz, Rose K.C., et al.
Publicado: (2021)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma
por: Burkard, Markus, et al.
Publicado: (2023)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model
por: Garofalo, Mariangela, et al.
Publicado: (2021)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010–2020—Cohort Study Based on Administrative Data
por: Datzmann, Thomas, et al.
Publicado: (2021)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients
por: Rossi, Ernesto, et al.
Publicado: (2023)

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
por: Brütting, Julia, et al.
Publicado: (2018)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1
por: Liu, Nian, et al.
Publicado: (2023)

Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma
por: Kim, Tae Woo, et al.
Publicado: (2022)

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis
por: Wu, Shuang, et al.
Publicado: (2021)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
por: Veerman, Rosanne E., et al.
Publicado: (2023)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

90. Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment
por: Youngster, Ilan, et al.
Publicado: (2019)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
por: Roger, Anissa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d2grfsner9rdiqj5cg8n2huc8d